CR11471A - MINERALCORTICOID RECEIVER ANTAGONIST AND USE METHODS - Google Patents
MINERALCORTICOID RECEIVER ANTAGONIST AND USE METHODSInfo
- Publication number
- CR11471A CR11471A CR11471A CR11471A CR11471A CR 11471 A CR11471 A CR 11471A CR 11471 A CR11471 A CR 11471A CR 11471 A CR11471 A CR 11471A CR 11471 A CR11471 A CR 11471A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compound
- formula
- mineralcorticoid
- use methods
- pharmaceutically acceptable
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000002395 mineralocorticoid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a un compuesto de Formula (I) o una sal del mismo farmaceuticamente aceptable; composiciones farmaceuticas que comprende un compuesto de Formula (I) en combinacion con un portador, diluyente o excipiente adecuado; y metodos para tratar trastornos fisiologicos, particularmente insuficiencia cardiaca congestiva, nefropatia diabetica, o enfermedad renal cronica, que comprende administrar un compuesto de Formula (I), o una sal del mismo farmaceuticamente aceptable.The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent or excipient; and methods for treating physiological disorders, particularly congestive heart failure, diabetic nephropathy, or chronic kidney disease, which comprises administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CR11471A CR11471A (en) | 2010-06-02 | 2010-06-02 | MINERALCORTICOID RECEIVER ANTAGONIST AND USE METHODS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CR11471A CR11471A (en) | 2010-06-02 | 2010-06-02 | MINERALCORTICOID RECEIVER ANTAGONIST AND USE METHODS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11471A true CR11471A (en) | 2010-09-27 |
Family
ID=44840181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11471A CR11471A (en) | 2010-06-02 | 2010-06-02 | MINERALCORTICOID RECEIVER ANTAGONIST AND USE METHODS |
Country Status (1)
| Country | Link |
|---|---|
| CR (1) | CR11471A (en) |
-
2010
- 2010-06-02 CR CR11471A patent/CR11471A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6300953A2 (en) | MINERALCORTICOID RECEIVER ANTAGONISTS AND METHODS OF USE | |
| PE20221914A1 (en) | SUBSTITUTE BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | |
| EA201490912A1 (en) | DERIVATIVES [1,2,3] TRIAZOLO [4,5-D] Pyrimidine as Agonists of Cannabinoid Receptor 2 | |
| EA201491060A1 (en) | NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE | |
| ECSP12011799A (en) | ESPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME COMPOUNDS | |
| EA201000091A1 (en) | DERIVATIVES OF MORFOLINOPYRIMIDINE USED IN DISEASES ASSOCIATED WITH mTOR KINASE AND / OR PI3K | |
| GT201200164A (en) | "NEW SPYROPIPERIDINE COMPOUNDS" | |
| BR112016010080A8 (en) | pyrazolopyrimidine compounds, pharmaceutical composition and their use | |
| PE20190405A1 (en) | FORMULATION FOR ANTI-alfa4beta7 ANTIBODY | |
| EA201491672A1 (en) | HETEROCYCLINE COMPOUNDS AS MEK INHIBITORS | |
| CL2011002989A1 (en) | Neutral endopeptidase (nep) inhibitor heterocyclic compounds; pharmaceutical composition; pharmaceutical combination; use of the compound to treat a disorder or disease such as hypertension, heart failure, kidney failure, epilepsy, metabolic syndrome, among others. | |
| ECSP15008695A (en) | PHARMACEUTICAL COMBINATIONS INCLUDING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR | |
| EA201290964A1 (en) | Peptide Conjugates of GLP-1 Receptor Agonists and Their Use | |
| UA104489C2 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| CR9304A (en) | GLUCAGON RECEIVER ANTAGONISTS, PREPARATIONS AND THERAPEUTIC USES | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| EA201301107A1 (en) | MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR (TFPI) | |
| AR124688A2 (en) | A PYRIMIDINE SULFONAMIDE OR A TAUTOMER THEREOF, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| AR085616A1 (en) | INHALABLE PHARMACEUTICAL COMPOSITION UNDERSTANDING GLICOPIRROLATE, USE | |
| EA201690888A1 (en) | NEW HETEROCYCLIC COMPOUNDS | |
| EA201491002A1 (en) | DERIVATIVES [1,2,3] TRIAZOLO [4,5-D] Pyrimidine as Agonists of Cannabinoid Receptor 2 | |
| PH12016500042A1 (en) | Stabilized pharmaceutical dosage forms comprising atrasentan | |
| MX2012013879A (en) | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases. | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| WO2015095097A3 (en) | Inhibitors of the renal outer medullary potassium channel |